Omeros (OMER)
(Delayed Data from NSDQ)
$3.92 USD
+0.11 (2.89%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $3.91 -0.01 (-0.26%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$3.92 USD
+0.11 (2.89%)
Updated Oct 11, 2024 04:00 PM ET
After-Market: $3.91 -0.01 (-0.26%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Zacks News
Analysts Estimate Omeros (OMER) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Omeros (OMER) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Omeros (OMER) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Omeros (OMER) delivered earnings and revenue surprises of 11.11% and -25.33%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Omeros (OMER) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Omeros (OMER) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Omeros (OMER) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Omeros (OMER) delivered earnings and revenue surprises of -2.50% and -23.88%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Should You Buy Omeros (OMER) Ahead of Earnings?
by Zacks Equity Research
Omeros (OMER) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
InMode (INMD) to Post Q1 Earnings: What's in the Offing?
by Zacks Equity Research
InMode's (INMD) Q1 performance is likely to have been driven by developments in business segments amid coronavirus-led supply disruptions.
Company News for Mar 4, 2020
by Zacks Equity Research
Companies in the news are: SCON, OMER, QGEN, TLRY
Omeros (OMER) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Omeros (OMER) delivered earnings and revenue surprises of 36.36% and 6.49%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Omeros (OMER) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Omeros (OMER) delivered earnings and revenue surprises of 47.37% and 3.60%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Here's Why You Should Hold on to Chemed (CHE) Stock Right Now
by Zacks Equity Research
Investors continue to be optimistic about Chemed's (CHE) performance.
Omeros (OMER) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Omeros (OMER) delivered earnings and revenue surprises of 64.44% and 8.09%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Will Omeros (OMER) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
Omeros (OMER) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Omeros (OMER) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Omeros (OMER) delivered earnings and revenue surprises of -11.76% and -4.73%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Will Omeros (OMER) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
Omeros (OMER) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What Makes Omeros (OMER) a Strong Momentum Stock: Buy Now?
by Zacks Equity Research
Does Omeros (OMER) have what it takes to be a top stock pick for momentum investors? Let's find out.
Omeros (OMER) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Omeros (OMER) delivered earnings and revenue surprises of 1.39% and 50.34%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Omeros (OMER) Q3 Earnings Expected to Decline
by Zacks Equity Research
Omeros (OMER) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Omeros (OMER) Surges: Stock Moves 10.2% Higher
by Zacks Equity Research
Omeros (OMER) saw a big move last session, as its shares jumped more than 10% on the day, amid huge volumes.
Omeros (OMER) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Omeros (OMER) delivered earnings and revenue surprises of 9.09% and -5.75%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
GW Pharma (GWPH) Q3 Earnings: Is a Turnaround in the Cards?
by Zacks Equity Research
GW Pharma (GWPH) is expected to report its fiscal third-quarter results next week. Investors focus is expected to be on the commercialization plan for Epidiolex.
These 3 Stocks Surged During Thursday's Sell-Off
by Benjamin Rains
Stocks saw rather large declines on Thursday, driven by concerns surrounding possible tariff-related retaliation from China against U.S. giants such as Boeing (BA), while Facebook's (FB) data breach woes escalated. These bellwethers helped contribute to a nearly 2.5% decline in the S&P 500 index as investors continue to assess the cost of rising interest rates and possible trade wars.
Omeros Inks Agreement With FDA for OMS721 Phase III Trial
by Zacks Equity Research
Omeros (OMER) inks an agreement with the FDA on Omeros' protocol for a phase III study to evaluate its lead pipeline candidate, OMS721, for treatment of patients with IgA nephropathy.
Can Omeros (OMER) Run Higher on Strong Earnings Estimate Revisions?
by Zacks Equity Research
Omeros (OMER) could be an interesting play for investors as it is seeing solid activity on the earnings estimate revision, along with decent short-term momentum.
Conatus' Liver Disease Drug Gets Orphan Drug Tag in the EU
by Zacks Equity Research
Conatus (CNAT) secures orphan drug designation for its pipeline candidate, IDN-7314, granted by the EMA. The candidate currently undergoes a phase II study on curing primary sclerosing cholangitis.
Omeros (OMER) Hits New 52-Week High on Positive FDA Decision
by Zacks Equity Research
Omeros Corporation (OMER) shares hit a new 52-week high of $22.80 on Thursday before eventually closing at $22.15.